Get the Stockscreener App
0.608
1.33%
0.008
After Hours:
.61
0.002
+0.33%
Equillium Inc stock is traded at $0.608, with a volume of 108.77K.
It is up +1.33% in the last 24 hours and down -15.33% over the past month.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
See More
Previous Close:
$0.60
Open:
$0.58
24h Volume:
108.77K
Relative Volume:
0.65
Market Cap:
$21.54M
Revenue:
$42.62M
Net Income/Loss:
$-8.32M
P/E Ratio:
-1.1472
EPS:
-0.53
Net Cash Flow:
$-15.77M
1W Performance:
-13.75%
1M Performance:
-15.33%
6M Performance:
-8.43%
1Y Performance:
-16.46%
1-Day Range:
$0.58
$0.6148
1-Week Range:
$0.5605
$0.7245
52-Week Range:
$0.5605
$3.25
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.608 | 21.54M | 42.62M | -8.32M | -15.77M | -0.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
Equillium Inc Stock (EQ) Latest News
Equillium stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Equillium Announces Board and Audit Committee Changes - TipRanks
Contrasting CSL (OTCMKTS:CSLLY) and Equillium (NASDAQ:EQ) - Defense World
Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge - Simply Wall St
Equillium CFO Jason Keyes sells $7,000 in stock By Investing.com - Investing.com Nigeria
Equillium CFO Jason Keyes sells $7,000 in stock - Investing.com
Equillium’s Q3 Financials and Clinical Progress in Focus - TipRanks
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - The Bakersfield Californian
Equillium to Present at the Stifel Healthcare Conference - The Bakersfield Californian
Equillium to Present Clinical Pipeline Updates at Stifel Healthcare Conference | EQ Stock News - StockTitan
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - BioSpace
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth - MSN
Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online
Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN
Ono says no to Equillium’s itolizumab - The Pharma Letter
Jones Trading Downgrades Equillium (EQ) - MSN
Equillium retains rights to itolizumab after Ono's option expires - Investing.com India
Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada
Equillium shares downgraded to hold from buy - Investing.com India
Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha
Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire
Equillium COO Christine Zedelmayer sells $18,750 in stock - Investing.com
Equillium COO Christine Zedelmayer sells $18,750 in stock By Investing.com - Investing.com Australia
Insider Sale: Sr. Vice President and COO Christine Zedelmayer Se - GuruFocus.com
Alto Ingredients And 2 Other US Penny Stocks To Watch Closely - Simply Wall St
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - StockTitan
Equillium CFO Jason Keyes sells $8,100 in company stock By Investing.com - Investing.com South Africa
Equillium CFO Jason Keyes sells $8,100 in company stock - Investing.com India
Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop - Simply Wall St
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Equillium executive sells $32,985 in stock - Investing.com India
Equillium executive sells $32,985 in stock By Investing.com - Investing.com Australia
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Yahoo Finance
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy - ForexTV.com
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - StockTitan
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Equillium Inc (EQ) - SETE News
Equillium Inc’s Market Journey: Closing Weak at 1.07, Down -0.93 - The Dwinnex
How should investors view Equillium Inc (EQ)? - US Post News
Equillium Inc Inc. (EQ) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):